Junko Kawahara, Bunji Kaku, Kunimasa Yagi, Naotaka Kitagawa, Maki Yokoyama, Yusuke Wakabayashi, Satoko Senda, Hiroyuki Takata, Yoshio Hiraiwa
Euglycemic diabetic ketoacidosis (eDKA) has emerged as an adverse event associated with sodium-glucose transporter-2 inhibitors (SGLT2i). We present two consecutive cases of SGLT2i-induced eDKA, both manifested as life-threatening coronary vasospastic angina (VSA). Case 1: A 64-year-old male overweight patient with type 2 diabetes (BMI 28.2 kg/m2 ), treated with dapagliflozin 5 mg daily for 6 months and a restricted diet for 2 months, experienced loss of consciousness following severe chest pain while driving, resulting in a traffic accident: plasma glucose, 163 mg/dL; urine ketones, (+++); bicarbonate (HCO3 - ), 13...
January 2024: Diabetology International